Login / Signup

High cure rates and tolerability of artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania.

Celine I MandaraFilbert FrancisMercy G ChiduoBilly NgasalaRenata MandikeSigsbert MkudeFrank ChackyFabrizio MolteniRitha NjauAlly MohamedMarian WarsameDeus S Ishengoma
Published in: Malaria journal (2019)
Both artemisinin-based combinations had high cure rates with PCR corrected ACPR of 100%. The two drugs had adequate safety with no SAE and all AEs were mild, and not associated with the anti-malarials. Continued TES is critical to monitor the performance of nationally recommended artemisinin-based combination therapy and supporting evidence-based review of malaria treatment policies. Trial registration This study is registered at ClinicalTrials.gov, No. NCT03431714.
Keyphrases
  • combination therapy
  • plasmodium falciparum
  • public health
  • clinical trial
  • phase iii
  • urinary tract infection
  • replacement therapy
  • placebo controlled